Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    INFLAMMATORY BOWEL DISEASE 24
Show Display Options
Rank Status Study
1 Recruiting An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase
Condition: Ulcerative Colitis
Interventions: Drug: Mesalazine Enema;   Drug: Placebo Enema
2 Completed A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
Condition: Crohn's Disease
Intervention: Drug: Certolizumab Pegol (CDP870)
3 Active, not recruiting Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Condition: Crohn's Disease
Interventions: Other: Cx601;   Other: Saline solution
4 Completed Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
Condition: Crohn's Disease
Intervention: Drug: Certolizumab Pegol (CDP870)
5 Completed
Has Results
Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease
Condition: Crohn's Disease
Intervention: Biological: Certolizumab pegol (CZP)
6 Completed
Has Results
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
Condition: Crohn's Disease
Intervention: Biological: Certolizumab pegol
7 Completed
Has Results
Canadian Active & Maintenance Modified Pentasa Study
Conditions: Active Ulcerative Colitis;   Remission of Ulcerative Colitis
Intervention: Drug: 5-ASA (5-Aminosalicylate)

Indicates status has not been verified in more than two years